KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AbbVie (ABBV) EBITDA (2016 - 2025)

AbbVie (ABBV) has disclosed EBITDA for 14 consecutive years, with $4.5 billion as the latest value for Q4 2025.

  • Quarterly EBITDA rose 404.97% to $4.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.1 billion through Dec 2025, up 64.99% year-over-year, with the annual reading at $15.1 billion for FY2025, 64.99% up from the prior year.
  • EBITDA for Q4 2025 was $4.5 billion at AbbVie, up from $1.9 billion in the prior quarter.
  • The five-year high for EBITDA was $5.5 billion in Q4 2022, with the low at -$1.5 billion in Q4 2024.
  • Average EBITDA over 5 years is $3.7 billion, with a median of $4.1 billion recorded in 2021.
  • The sharpest move saw EBITDA soared 490.56% in 2021, then tumbled 146.64% in 2024.
  • Over 5 years, EBITDA stood at $5.1 billion in 2021, then increased by 8.44% to $5.5 billion in 2022, then plummeted by 41.93% to $3.2 billion in 2023, then crashed by 146.64% to -$1.5 billion in 2024, then surged by 404.97% to $4.5 billion in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $4.5 billion, $1.9 billion, and $4.9 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.